The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine
The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine
复制标题
DOI：
10.1592/phco.20.6.549.35162
复制
发表时间：
2000-05-01
期刊：
影响因子：
4.1
通讯作者：
Davey, R
中科院分区：
文献类型：
--
作者：
Piscitelli, SC;Kress, DR;Davey, R
研究目标。目的：测定利托那韦对哌替啶和去甲哌替啶药动学的影响。开放标签，交叉，药代动力学研究。美国政府研究医院研究对象八名健康志愿者人类免疫缺陷病毒检测呈阴性干预。受试者口服哌替啶50 mg，连续采集血液48小时。然后给予利托那韦500毫克，每天两次，连续10天，随后给予第二剂50毫克的哌替啶，并收集系列样品。测量和主要结果。检测血浆样品中哌替啶、去甲哌替啶和利托那韦的含量。在利托那韦存在的情况下，所有受试者的哌嗪曲线下面积（AUC）平均下降了67±- 4% (p
Study Objective. To determine the effects of ritonavir on the pharmacokinetics of meperidine and normeperidine.Design. Open-label, crossover, pharmacokinetic study.Setting. United States government research hospital.Subjects. Eight healthy volunteers who tested negative for the human immunodeficiency virus.Intervention. Subjects received oral meperidine 50 mg and had serial blood samples collected for 48 hours. They then received ritonavir 500 mg twice/day for 10 days, followed by administration of a second 50-mg meperidine dose and collection of serial samples.Measurements and Main Results. Plasma samples were assayed for meperidine, normeperidine, and ritonavir. Meperidine's area under the curve (AUC) decreased in all subjects by a mean of 67 +/- 4% in the presence of ritonavir (p